About Citryll

Citryll is pioneering an innovative approach to immune mediated inflammatory diseases. Targeting NETs as a fundamental but previously unaddressed component of inflammation, Citryll is going beyond individual pathway management and symptom treatment to reduce inflammatory drive at the source.

OUR TEAM
board of directors
Investors
Careers

Our science and products

Citryll’s lead asset, CIT-013, targets NETs via a dual mechanism of action, inhibiting the formation of new NETs and enhancing the clearance of existing NETs. This is achieved by binding to citrullinated histones. By addressing this fundamental component of inflammation, CIT-013 represents a transformative new treatment alternative for diseases with high unmet medical needs.

Citryll’s targeted approach has applications in many inflammatory diseases. Its current focus is on Rheumatoid Arthritis (RA) and Hidradenitis Suppurativa (HS), with clinical development programs underway for both diseases. Trials in RA and HS are intended to establish proof-of-concept for CIT-013’s NET targeting approach. Citryll has the potential to create a new class of therapeutics for a wide range of immune-mediated inflammatory diseases.